Latest Regulatory News

Kingston Resources has agreed to sell its Misima Gold-Silver Project for $95 million, bolstering its balance sheet to accelerate growth at the Mineral Hill gold-copper operation. The transaction positions Kingston to expand production and exploration in the southern Cobar Basin.

Sunstone Metals Ltd has had its trading suspension lifted following a Federal Court decision and the release of a cleansing prospectus, signaling a fresh chapter for the mining company on the ASX.

Zoono Group has inked a five-year exclusive contract with Sharpak and OSY to apply its antimicrobial technology on UK soft fruit packaging, aiming to reduce food waste and boost shelf-life.

Clarity Pharmaceuticals has initiated its second registrational Phase III AMPLIFY trial for the Cu-SAR-bisPSMA PET imaging agent targeting biochemical recurrence of prostate cancer. The multi-centre study aims to generate critical data supporting FDA approval and could redefine prostate cancer diagnostics.

Atomo Diagnostics has released a Target Market Determination for a new capital raising involving options and shares, including a $1 million Share Purchase Plan and placement offer. The move targets eligible Australian shareholders and aims to bolster the company’s financial position amid a speculative investment environment.

Atomo Diagnostics Limited has announced a capital raising initiative comprising a Share Purchase Plan (SPP) and a Placement, aiming to raise up to $1 million through the SPP and additional funds via a Placement, subject to shareholder approval at a June 23 meeting.

Riversgold Limited reports metallurgical tests confirming over 90% gold recovery at its Northern Zone project near Kalgoorlie, alongside promising drilling results that pave the way for a maiden resource estimate.

Breakthrough Minerals has resolved a critical regulatory issue allowing the Errolls Gold Project acquisition to proceed, with drilling set to begin next quarter targeting high-grade gold extensions.

Sayona Mining reports solid FY25 operational gains and outlines strategic merger progress with Piedmont Lithium, positioning itself as a leading North American lithium producer amid a recovering market.

Avecho Biotechnology has expanded its pivotal Phase III clinical trial for a CBD insomnia treatment by adding new recruitment sites and partnering with pharmaceutical giant Sandoz to boost patient enrolment and regulatory progress.

FFI Holdings Limited has announced a pro-rata non-renounceable entitlement offer priced at $3.50 per share, aiming to raise approximately $11 million to support its food manufacturing growth and property investments. The offer closes on 17 June 2025 and is open to eligible shareholders in Australia and New Zealand.

FFI Holdings has announced a $11 million non-renounceable entitlement offer priced at $3.50 per share, representing a notable discount to recent trading levels. The capital raise aims to fund property development and reduce debt, with directors backing the move by fully participating.